Biotech

Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 14 May 2025. Incannex Healthcare (NASDAQ: IXHL) shares closed up 866% at US$0.82 following the completion of patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study evaluating IHL-42X for obstructive sleep apnea (OSA). Bluebird Bio (NASDAQ: BLUE), Carlyle, and SK Capital amended their acquisition agreement. Bluebird stockholders can now choose between US$3.00 per share plus a US$6.84 CVR upon achieving a sales milestone, or US$5.00 p Aytu BioPharma (NASDAQ: AYTU) reported quarterly earnings of US$0.21 per share, exceeding analyst estimates losses of US$0.17 by 223.5% and marking a 140.4% improvement from last year’s US$0.52 loss. Quarterly sales re Septerna (NASDAQ: SEPN) and Novo Nordisk (NASDAQ: NVO) have entered an exclusive global collaboration to discover, develop, and commercialize oral small-molecule medicines for obesity, type 2 diabetes, and other cardio Plus Therapeutics (NASDAQ: PSTV) is expected to report increased earnings on higher revenue for the quarter ending March 2025. Consensus estimates project a US$0.17 per share loss and US$1.85m in revenue. Surpassing th Quoin Pharmaceuticals (NASDAQ: QNRX) observed clear skin improvement in a pediatric peeling skin syndrome study after 12 weeks. Key endpoints showed significant improvement, and the treatment QRX003 was well-tolerated. Allurion Technologies (NASDAQ: ALUR) shares closed up 26% at US$3 following obesity data. Studies highlighted weight loss and muscle gain with their balloon and AI-powered care, both with and without GLP-1s. Combining

Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 23 April 2025.Ensysce Biosciences (NASDAQ: ENSC) received a USPTO Notice of Allowance for a patent covering composition and method claims for PF9001, a methadone prodrug using its TAAP and MPAR technologies to improve safety in opioid use disorder treatment. Shares closed up 96% at US$3.67.

Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 4 April 2025.Renovaro Biosciences (NASDAQ:RENB) announced that Predictive Oncology (NASDAQ: POAI) terminated their merger agreement, which Renovaro claims is a breach of binding agreements. Renovaro is demanding compliance with the deal, including an exclusive license agreement, and may pursue legal action if unNeuroOne Medical (NASDAQ: NMTC) announced the pricing of an US$8 million underwritten registered public offering of 16m shares of its common stock for US$0.50 per share. Shares closed down 45% at US$0.48.Sarepta Therapeutics (NASDAQ: SRPT) reported that an independent data monitoring committee reviewed safety data for ELEVIDYS after EU regulators flagged liver failure concerns. The committee upheld a favorable benefit-risk profile, allowing paused trials to continue. Sarepta and Roche will submit fiSangamo Therapeutics (NASDAQ: SGMO) licensed its STAC-BBB AAV capsid to Eli Lilly for CNS disease treatments, securing an US$18 million upfront fee and potential milestone payments up to US$1.4 billion, plus tiered royalties on future sales. Shares closed up 6% at US$0.66.Dynavax Technologies (NASDAQ: DVAX) filed preliminary proxy materials ahead of its 2025 annual meeting, highlighting ongoing strategy execution and nominating four independent directors (Brent MacGregor, Scott Myers, Lauren Silvernail, and Elaine Sun) for reelection. Shares closed down 2% at US$12.6Arvinas (NASDAQ: ARVN) reported first-in-human Phase 1 data for ARV-102, showing it was well tolerated and achieved robust, dose-dependent LRRK2 degradation in CSF and blood, supporting continued development in Parkinson’s and related neurodegenerative diseases. Shares closed down 5% at US$6.56.OS Therapies (NASDAQ: OSTX) received a Buy rating and a US$19.00 price target from Lake Street. Shares closed down 9% at US$1.4.

V小姐

2 months ago

Global Healthcare Weekly

In our global healthcare weekly, we focus on identifiying key stock catalysts for biotech companies this week. Atara Biotherapeutics (NASDAQ: ATRA) with a market cap of around $41.8 million, focuses on developing T-cell immunotherapies for cancers and autoimmune diseases. The firm’s lead candidate,